<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00888459</url>
  </required_header>
  <id_info>
    <org_study_id>07-008574</org_study_id>
    <secondary_id>CA121165</secondary_id>
    <nct_id>NCT00888459</nct_id>
  </id_info>
  <brief_title>A Pilot Study Evaluating Nicotine Lozenges and Self Help</brief_title>
  <official_title>A Pilot Study to Assess the Effectiveness of the Nicotine Lozenge for Smokeless Tobacco Users</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oregon Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are hypothesizing that by offering both self-help materials and mailed
      nicotine lozenges we will be able to help increase tobacco abstinence rates among ST users,
      as well as decrease tobacco withdrawal.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Smokeless tobacco (ST) is a known human carcinogen. Long-term ST use is known to increase the
      risk for oropharyngeal cancer. Most smokeless tobacco users wish to quit. Assisted-self help
      interventions (i.e., self-help manual, a targeted video, and two support telephone phone
      calls) have been shown to be superior to manual-only interventions for increasing tobacco
      abstinence rates. These interventions lend themselves to widespread dissemination, but
      abstinence rates at 6 months remains low (21%). Providing nicotine replacement therapy (NRT)
      to ST users receiving assisted self-help interventions could improve upon these ST abstinence
      rates. If found to be effective, this intervention may increase the ability to disseminate
      effective interventions to a population of tobacco users for whom few treatment resources
      currently exist.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Tobacco Abstinence</measure>
    <time_frame>12 weeks</time_frame>
    <description>self-reported 7-day point prevalence tobacco abstinence at week 12 (end of treatment)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Smokeless Tobacco Use</condition>
  <arm_group>
    <arm_group_label>active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Self-help counseling material and 4 mg nicotine lozenges</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>self help counseling material and placebo nicotine lozenges</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nicotine replacement therapy</intervention_name>
    <description>4 mg nicotine lozenges, ad lib, for 12 weeks.</description>
    <arm_group_label>active</arm_group_label>
    <other_name>Nicotine Lozenges</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo NRT</intervention_name>
    <description>Placebo nicotine lozenges</description>
    <arm_group_label>2</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. male;

          2. ≥18 years of age;

          3. report ST as their primary tobacco of use;

          4. have used ST daily for the past 6 months;

          5. indicate that they want to quit;

          6. have been provided with, understand, and have signed the informed consent.

        Exclusion Criteria:

          1. previously enrolled in a study involving the use of the nicotine lozenge;

          2. currently using or have completed using (past 30 days) any other behavioral or
             pharmacologic tobacco treatment program;

          3. currently enrolled in another research study;

          4. describe having a medical history of: a) unstable angina; b) myocardial infarction
             within the past 6 months; c) cardiac dysrhythmia other than medication-controlled
             atrial fibrillation or PSVT; or d) medically-treated or untreated hypertension with BP
             ≥ 180 systolic OR ≥ 100 diastolic;

          5. have phenylketonuria (PKU) [nicotine lozenges contain aspartame which is metabolized
             to phenylalanine and not processed in individuals with PKU];

          6. have another member of their household already participating in this study;

          7. have other medical or psychiatric conditions that would exclude the participant;

          8. have a score of ≥ 15 on the Patient Health Questionnaire (PHQ-9) on the phone call
             pre-screen.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jon O Ebbert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Research Institute</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Ebbert JO, Severson HH, Croghan IT, Danaher BG, Schroeder DR. A pilot study of mailed nicotine lozenges with assisted self-help for the treatment of smokeless tobacco users. Addict Behav. 2010 May;35(5):522-5. doi: 10.1016/j.addbeh.2009.12.020. Epub 2010 Jan 4.</citation>
    <PMID>20060229</PMID>
  </results_reference>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2009</study_first_submitted>
  <study_first_submitted_qc>April 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2009</study_first_posted>
  <results_first_submitted>October 4, 2010</results_first_submitted>
  <results_first_submitted_qc>October 4, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 4, 2010</results_first_posted>
  <last_update_submitted>July 14, 2011</last_update_submitted>
  <last_update_submitted_qc>July 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2011</last_update_posted>
  <responsible_party>
    <name_title>Jon Ebbert, MD</name_title>
    <organization>Mayo Clinic</organization>
  </responsible_party>
  <keyword>tobacco</keyword>
  <keyword>chew</keyword>
  <keyword>nrt</keyword>
  <keyword>nicotine lozenges</keyword>
  <keyword>self-help</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The first person was pre-screened on 05/20/08 and the last person was randomized on 09/29/08.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Active</title>
          <description>4 mg nicotine lozenges</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>placebo nicotine lozenges (similar in appearance to the 4 mg lozenge)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active</title>
          <description>4 mg nicotine lozenges</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>placebo nicotine lozenges (similar in appearance to the 4 mg lozenge)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.6" spread="16.0"/>
                    <measurement group_id="B2" value="42.4" spread="11.7"/>
                    <measurement group_id="B3" value="43.0" spread="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smokeless tobacco</title>
          <units>cans/week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.9" spread="3.1"/>
                    <measurement group_id="B2" value="3.7" spread="2.1"/>
                    <measurement group_id="B3" value="3.8" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Tobacco Abstinence</title>
        <description>self-reported 7-day point prevalence tobacco abstinence at week 12 (end of treatment)</description>
        <time_frame>12 weeks</time_frame>
        <population>intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Active</title>
            <description>4 mg nicotine lozenges</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo nicotine lozenges (similar in appearance to the 4 mg lozenge)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Tobacco Abstinence</title>
          <description>self-reported 7-day point prevalence tobacco abstinence at week 12 (end of treatment)</description>
          <population>intention to treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.432</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Active</title>
          <description>4 mg nicotine lozenges</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>placebo nicotine lozenges (similar in appearance to the 4 mg lozenge)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Sleep disturbance</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jon O. Ebbert</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-266-1944</phone>
      <email>ebbert.jon@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

